medscape.com
Summary
Psychedelic policy and clinical practice in Europe are being shaped by a Swiss model. The page connects Switzerland's early role in developing a framework for psychedelic use with broader European follow-on efforts, implying growing international convergence on regulation, access pathways, and evidence standards. The focus is on how national experiences translate into cross-border momentum for psychedelics as healthcare and research topics, rather than on a single drug or treatment protocol.